Aldeyra Therapeutics, Inc. announced that David J. Clark, M.D. has joined the company as its Chief Medical Officer, effective January 11, 2016. Dr. Clark will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. Dr. Clark has 18 years of clinical development experience with big pharma and biotech companies based in the US and EU.

Most recently, he served as chief medical officer of Wilson Therapeutics where he led the company's Phase 2 program for Wilson Disease and the clinical development planning for its Phase 3 program, including detailed interactions with FDA and EMA. Previously, he held senior medical positions at TransTech Pharma and NormOxys, two biotechnology companies focused on the development of drug candidates in a variety of therapeutic areas, including oncology, cardiovascular and neuroscience.